Structure Therapeutics director granted 39,453 options

Structure Therapeutics Inc. director Ted W. Love received a grant of share options, giving him the right to buy 39,453 Ordinary Shares.

Rhea-AI Filing Summary

Structure Therapeutics Inc. director Ted W. Love received a grant of share options, giving him the right to buy 39,453 Ordinary Shares. The options have an exercise price of $15.00 per share, set at the fair market value on the grant date.

The options vest in equal monthly installments over the 12 months following June 17, 2026 and will be fully vested immediately before the company’s 2027 annual shareholder meeting. Each American Depositary Share represents three Ordinary Shares.

Insider Trade Summary

Grant/Award: 39,453 shares

Grant/Award 1 txn

Insider LOVE TED W

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (right to buy)	39,453	$0.00	$0.00

Holdings After Transaction: Share Option (right to buy) — 39,453 contracts (Direct)

Footnotes (3)

1. F1. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").
2. F2. The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting,
3. F3. The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

Key Figures

Options granted: 39,453 options Exercise price: $15.00 per Ordinary Share Underlying shares: 39,453 Ordinary Shares +4 more

7 metrics

Options granted 39,453 options Share Option grant to director Ted W. Love

Exercise price $15.00 per Ordinary Share Option exercise price set at fair market value on grant date

Underlying shares 39,453 Ordinary Shares Shares underlying the granted options

Expiration date June 16, 2036 Option expiration if not exercised earlier

Vesting period 12 months Equal monthly vesting following June 17, 2026

ADS to Ordinary ratio 1 ADS = 3 Ordinary Shares Representation of Ordinary Shares via ADSs

Post-grant derivative holdings 39,453 options Total options held following this transaction

Key Terms

Share Option (right to buy), fair market value, American Depositary Shares ("ADSs"), Ordinary Shares, +1 more

5 terms

Share Option (right to buy) financial

"security_title: "Share Option (right to buy)""

fair market value financial

"The option exercise price per share is equal to the fair market value per Ordinary Share"

The price a willing buyer and a willing seller would agree on for an asset or security when neither is under pressure and both have access to the same information. Think of it as the market’s neutral estimate of what something is worth, like the price two neighbors would settle on for a car after comparing similar listings. Investors care because fair market value guides buying and selling decisions, tax reporting, portfolio valuation, and how accurately company assets are reflected in financial statements.

American Depositary Shares ("ADSs") financial

"based on the trading price of the Issuer's American Depositary Shares ("ADSs")"

American Depositary Shares (ADSs) are U.S.-listed certificates issued by a bank that represent ownership of a specified number of a foreign company’s ordinary shares, letting U.S. investors buy and sell those interests in U.S. dollars on American markets. They matter because they make investing in overseas companies as easy as buying a domestic stock—streamlining currency, settlement, and recordkeeping—while still exposing investors to foreign-market risks like exchange rates and local regulations.

Ordinary Shares financial

"The Ordinary Shares of the Issuer may be represented by ADSs."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

vest financial

"The shares vest in equal monthly installments over the 12 months"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ted W. Love report in this Form 4 for GPCR?

Ted W. Love reported receiving a grant of 39,453 share options in Structure Therapeutics Inc. The options are compensation-based, not an open-market purchase, and give him the right to buy Ordinary Shares at a fixed exercise price.

How many options did the Structure Therapeutics (GPCR) director receive?

The director received 39,453 share options linked to Structure Therapeutics Ordinary Shares. These options represent the right to acquire 39,453 underlying Ordinary Shares, subject to vesting, at a fixed exercise price specified in the grant terms described in the Form 4.

What is the exercise price of the options granted to the GPCR director?

The options have an exercise price of $15.00 per Ordinary Share. This price equals the fair market value on the grant date, determined using the trading price of Structure Therapeutics American Depositary Shares referenced in the filing’s footnotes.

How do the options granted to the Structure Therapeutics director vest?

The options vest in equal monthly installments over the 12 months following June 17, 2026. Regardless of this schedule, the grant will be fully vested immediately before Structure Therapeutics’ 2027 annual shareholder meeting, according to the filing’s footnotes.

When do the options granted to the GPCR director expire?

The options expire on June 16, 2036, if not exercised earlier. After this expiration date, the right to purchase the underlying Ordinary Shares under this specific grant will lapse and no longer be exercisable by the reporting person.

How are Structure Therapeutics Ordinary Shares represented by ADSs?

Structure Therapeutics states that its Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents three Ordinary Shares, providing a ratio that helps investors relate the option grant to the ADS trading framework.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 05:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LOVE TED W

(Last) (First) (Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$15(1)	06/17/2026		A		39,453		(2)	06/16/2036	Ordinary Shares	39,453(3)	$0	39,453	D

Explanation of Responses:

1. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").

2. The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting,

3. The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

	/s/ Jun Yoon, Attorney-in-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)